Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06831474 · ClinicalTrials.gov registry record · Phase 1

Excretion of Rivaroxaban in Human Breast Milk

A Phase 1 study of Breastfeeding and Postpartum, sponsored by Thomas Jefferson University.

Recruiting
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT06831474 is a Phase 1 study of Breastfeeding and Postpartum that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 10 participants, below the 718-participant average among 28 other Breastfeeding trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06831474, a Phase 1 study of Breastfeeding and Postpartum, is actively recruiting participants, sponsored by Thomas Jefferson University.

RECRUITING
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate the distribution of rivaroxaban into human milk at both therapeutic and prophylactic doses, and over time with repeated dosing.

Interventions

  • DRUG Rivaroxaban 10 MG Oral Tablet
  • DRUG Rivaroxaban 20 MG Oral Tablet

Study Locations (1)

Pennsylvania

  • Thomas Jefferson University Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2025-07
Est. Completion 2026-07-31
Phase Phase 1

Sponsor

Thomas Jefferson University

292 total trials

What the Registry Record Tells You About NCT06831474

The ClinicalTrials.gov registry entry for NCT06831474 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 718-participant average among 28 other Breastfeeding trials with a reported enrollment target (99% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Breastfeeding appearing as the primary indexed condition, and to 2 interventions - of which Rivaroxaban 10 MG Oral Tablet is the first listed.

NCT06831474 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06831474 about?

NCT06831474 is a clinical study titled "Excretion of Rivaroxaban in Human Breast Milk". The purpose of this study is to investigate the distribution of rivaroxaban into human milk at both therapeutic and prophylactic doses, and over time with repeated dosing.

What is the current status of trial NCT06831474?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-07. Estimated completion is 2026-07-31.

What conditions does trial NCT06831474 study?

This clinical trial studies the following conditions: Breastfeeding, Postpartum, Breast Milk Collection, VTE (Venous Thromboembolism), VTE Prophylaxis.

What interventions are being tested in trial NCT06831474?

The interventions under investigation include: Rivaroxaban 10 MG Oral Tablet (DRUG), Rivaroxaban 20 MG Oral Tablet (DRUG).

Who is sponsoring clinical trial NCT06831474?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06831474 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breastfeeding

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.